1. NF-κB
  2. NF-κB
  3. Pyrrolidinedithiocarbamate ammonium

Pyrrolidinedithiocarbamate ammonium  (Synonyms: Ammonium pyrrolidinedithiocarbamate; PDTC ammonium; APDC)

Cat. No.: HY-18738 Purity: ≥98.0%
SDS COA Handling Instructions Technical Support

Pyrrolidinedithiocarbamate ammonium (Ammonium pyrrolidinedithiocarbamate) is a selective and blood-brain barrier (BBB) permeable NF-κB inhibitor.

For research use only. We do not sell to patients.

Pyrrolidinedithiocarbamate ammonium Chemical Structure

Pyrrolidinedithiocarbamate ammonium Chemical Structure

CAS No. : 5108-96-3

Size Price Stock Quantity
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 124 publication(s) in Google Scholar

Top Publications Citing Use of Products

109 Publications Citing Use of MCE Pyrrolidinedithiocarbamate ammonium

WB
Proliferation Assay
RT-PCR
Cell Viability Assay

    Pyrrolidinedithiocarbamate ammonium purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2023 Feb 24.  [Abstract]

    Pyrrolidinedithiocarbamate ammonium (PDTC; 100 μM; 24 h) decreases viability of HepG2 and Huh7 cells on the basis of aspirin.

    Pyrrolidinedithiocarbamate ammonium purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2022 Sep;12(9):3618-3638.

    SCT2 depletion-senescent LX2 cells are treated with rIL-1α protein and addressed in NF-κB inhibitor PDTC (100 μM), and the analysis of mRNAs of proinflammatory SASP IL1A, IL1B, IL6 and IL8 by qPCR.

    Pyrrolidinedithiocarbamate ammonium purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2022 Jun;12(6):e850.  [Abstract]

    PEMs are treated with the NF-κB inhibitor PDTC (100 μM) for 1 h followed by BSA or UGRP1 (0.5 μg/mL) treatment and Pam3CSK4 stimulation for 6 h to measure Il6 mRNA by qRT‐PCR .

    Pyrrolidinedithiocarbamate ammonium purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2022 Jun;12(6):e850.  [Abstract]

    PEMs are treated with the NF-κB inhibitor PDTC (100 μM) for 1h followed by BSA or UGRP1 (0.5 μg/mL) treatment for 6 h, then stimulated by Pam3CSK4 for 0.5 h, p65 in the whole cell lysate and nucleus is analysed by immunoblot.

    Pyrrolidinedithiocarbamate ammonium purchased from MedChemExpress. Usage Cited in: JACC Basic Transl Sci. 2022 Aug 3;7(8):820-840.

    To pharmacologically inhibit NFκB, mice are given Pyrrolidinedithiocarbamate ammonium (PDTC; 100 mg/kg).

    Pyrrolidinedithiocarbamate ammonium purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2022 Oct 21;S0141-8130(22)02401-1.

    TLR4 and downstream pathways are subjected to relevant western blotting. After the treatment with TJ-M2010, TRAF-stop, and PDTC (5 μM) for 1 h, DCs are stimulated with 10 μg/mL CARP2 for 0, 45, and 90 min.

    Pyrrolidinedithiocarbamate ammonium purchased from MedChemExpress. Usage Cited in: Oncogene. 2022 Mar;41(13):1866-1881.  [Abstract]

    The Cxcl10 mRNA expression in B16F0 cells treated with IFNα (1 000 U/ml) for 12 hours, in presence of PDTC (10 μM) or BAY 11-7082 (5 μM).

    Pyrrolidinedithiocarbamate ammonium purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Jan 19;11(7):3392-3416.  [Abstract]

    Treatment with NF-κB (PDTC) inhibitor in both PC9 and H1975 cells treated with different concentrations of specific inhibitor for 72 h and Western blotting is performed.

    Pyrrolidinedithiocarbamate ammonium purchased from MedChemExpress. Usage Cited in: Redox Biol. 2021 Oct;46:102098.

    Several specific pharmacological inhibitors, including Pyrrolidine dithiocarbamate (PDTC, 100 μM), Wortmannin (Wort), Stattic, PD98059 and Bisindolylmaleimide I (Bis), are pre-administered to the cardiomyocytes in the HG + Pae group and then the expression of Opa1 is quantified.

    Pyrrolidinedithiocarbamate ammonium purchased from MedChemExpress. Usage Cited in: EMBO Rep. 2021 Jul 5;22(7):e51678.  [Abstract]

    qPCR analysis of Mmps including Mmp9, Mmp10, and Mmp12 from THP‐1 cells stimulated with AG (1 μg/mL) for 24 h in the absence or presence of PDTC at the concentration of 10 μM.

    Pyrrolidinedithiocarbamate ammonium purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2019 Jan 24;15(3):688-700.  [Abstract]

    T24 cells are treated with PDTC at various concentrations for 24-h, and cell viability and IC50 values are measured using MTS assays.

    Pyrrolidinedithiocarbamate ammonium purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Feb 8;10(2):113.   [Abstract]

    RAW cells are pre-treated with rMMP-9 and/or PDTC (50 μM) 1 h followed by 18 h of PBS/LPS challenged, and then expressions of representative M1 marker genes.

    Pyrrolidinedithiocarbamate ammonium purchased from MedChemExpress. Usage Cited in: Oncoimmunology. 2018 Aug 23;7(11):e1461303.  [Abstract]

    The expression of Oct4 in A549 and H460 cells treated with or without rhIL-17A and these molecular inhibitors (NF-kB inhibitor: PDAC, Notch1 inhibitor: LY411575) are assessed by western blotting.

    Pyrrolidinedithiocarbamate ammonium purchased from MedChemExpress. Usage Cited in: Oncoimmunology. 2018 Aug 23;7(11):e1461303.  [Abstract]

    The expression of Oct4 in A549 and H460 cells treated with or without rhIL-17A and these molecular inhibitors (NF-kB inhibitor: PDAC, Notch1 inhibitor: LY411575) are assessed by western blotting.

    Pyrrolidinedithiocarbamate ammonium purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2017;2017:3869561.  [Abstract]

    N-formyl-Met-Leu-Phe (fMLP; 10 nM) are used to stimulate the cells for 2 min, and the polymorphonuclear neutrophils (PMNs) without fMLP serve as the control. NPS-2143 (100 nM), AMG 073 (100 nM), and PDTC (100 nM) are added and incubated. Protein expression results are representative of three experiments.

    View All NF-κB Isoform Specific Products:

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Pyrrolidinedithiocarbamate ammonium (Ammonium pyrrolidinedithiocarbamate) is a selective and blood-brain barrier (BBB) permeable NF-κB inhibitor.

    IC50 & Target[1]

    NF-κB

     

    Cellular Effect
    Cell Line Type Value Description References
    ACHN GI50
    0.23 μM
    Compound: PDTC
    Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    [PMID: 25953156]
    BV-2 IC50
    10.8 μM
    Compound: PDTC
    Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
    Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
    [PMID: 28169537]
    HCT-15 GI50
    0.13 μM
    Compound: PDTC
    Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    [PMID: 25953156]
    Jurkat IC50
    5.12 μM
    Compound: Pyrrolidinedithiocarbamate
    Antiinflammatory activity in PMA induced human Jurkat cells assessed as inhibition of IL-2 production by EIA assay
    Antiinflammatory activity in PMA induced human Jurkat cells assessed as inhibition of IL-2 production by EIA assay
    [PMID: 36496202]
    MDA-MB-231 GI50
    0.16 μM
    Compound: PDTC
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    [PMID: 25953156]
    NCI-H23 GI50
    0.1 μM
    Compound: PDTC
    Cytotoxicity against human NCI-H23 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human NCI-H23 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    [PMID: 25953156]
    NUGC-3 GI50
    0.14 μM
    Compound: PDTC
    Cytotoxicity against human NUGC3 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human NUGC3 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    [PMID: 25953156]
    PC-3 GI50
    0.17 μM
    Compound: PDTC
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    [PMID: 25953156]
    RAW264.7 IC50
    34.5 μM
    Compound: PDTC
    Inhibition of NF-kappaB (unknown origin) transcriptional activity in LPS-induced mouse RAW264.7 cells after 1 hr by secreted alkaline phosphatase assay
    Inhibition of NF-kappaB (unknown origin) transcriptional activity in LPS-induced mouse RAW264.7 cells after 1 hr by secreted alkaline phosphatase assay
    [PMID: 25953156]
    RAW264.7 IC50
    37 μM
    Compound: PDTC
    Inhibition of NF-kappaB (unknown origin) expressed in mouse RAW264.7 cells pretreated for 1 hr followed by stimulation with LPS measured after 6 hrs by luciferase reporter gene assay
    Inhibition of NF-kappaB (unknown origin) expressed in mouse RAW264.7 cells pretreated for 1 hr followed by stimulation with LPS measured after 6 hrs by luciferase reporter gene assay
    [PMID: 26928174]
    RAW264.7 IC50
    37.2 μM
    Compound: PDTC
    Inhibition of LPS-induced NFkappaB (unknown origin) transcriptional activity expressed in mouse RAW264.7 cells incubated for 16 hrs by SEAP based reporter gene assay
    Inhibition of LPS-induced NFkappaB (unknown origin) transcriptional activity expressed in mouse RAW264.7 cells incubated for 16 hrs by SEAP based reporter gene assay
    [PMID: 27096046]
    RAW264.7 IC50
    37.2 μM
    Compound: PDTC
    Inhibition of transcriptional activity of NF-kappaB (unknown origin) transfected in LPS-stimulated mouse RAW264.7 cells after 16 hrs by secretory alkaline phosphatase reporter gene assay
    Inhibition of transcriptional activity of NF-kappaB (unknown origin) transfected in LPS-stimulated mouse RAW264.7 cells after 16 hrs by secretory alkaline phosphatase reporter gene assay
    [PMID: 24792464]
    THP-1 IC50
    6.11 μM
    Compound: Pyrrolidinedithiocarbamate
    Antiinflammatory activity in LPS induced human THP-1 cells assessed as inhibition of TNF-alpha production by EIA assay
    Antiinflammatory activity in LPS induced human THP-1 cells assessed as inhibition of TNF-alpha production by EIA assay
    [PMID: 36496202]
    U-937 IC50
    8.3 μg/mL
    Compound: PDTC
    Inhibition of etoposide-induced caspase 3 induction in human U937 cells after 7 hrs
    Inhibition of etoposide-induced caspase 3 induction in human U937 cells after 7 hrs
    [PMID: 11908994]
    U-937 IC50
    8.3 μg/mL
    Compound: PDTC
    Inhibition of etoposide-induced apoptosis in human U937 cells assessed as inhibition of caspase 3 induction after 7 hrs
    Inhibition of etoposide-induced apoptosis in human U937 cells assessed as inhibition of caspase 3 induction after 7 hrs
    [PMID: 11374970]
    In Vitro

    Pretreatment of cells with Pyrrolidinedithiocarbamate ammonium (Ammonium pyrrolidinedithiocarbamate; 3-1000 μM) dose-dependently attenuate IL-8 production[1].
    Furthermore, pyrrolidinedithiocarbamate ammonium (100 μM) suppresses the accumulation of IL-8 mRNA[1].
    Pyrrolidinedithiocarbamate ammonium inhibits the activation of NF-κB, because it suppresses both NF-κB DNA binding and NF-κB-dependent transcriptional activity. NF-κB inhibition with pyrrolidinedithiocarbamate ammonium decrease IL-8 production by intestinal epithelial cells[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    The DSS+pyrrolidinedithiocarbamate ammonium-treated groupII exhibits suppression of shortening of intestinal length and reduction of DAI score. Activated NF-κB level and IL-1β and TNF-α levels are significantly lower in DSS+pyrrolidinedithiocarbamate ammonium-treated groupII. These findings suggest that suppression of NF-κB activity by pyrrolidinedithiocarbamate ammonium can delay the healing of mucosal tissue defects (erosions or ulcers) arising from inflammation, but that it can strongly suppress the expression of inf-lammatory cytokines (IL-1β and TNF-α), resulting in significant alleviation of colitis. pyrrolidinedithiocarbamate ammonium is useful for the treatment of ulcerative colitis[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    164.29

    Formula

    C5H12N2S2

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    SC(N1CCCC1)=S.N

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (608.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 50 mg/mL (304.34 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 6.0868 mL 30.4340 mL 60.8680 mL
    5 mM 1.2174 mL 6.0868 mL 12.1736 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 5 mg/mL (30.43 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 5 mg/mL (30.43 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 24 mg/mL (146.08 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: ≥98.0%

    References
    Cell Assay
    [1]

    The human colon cancer cell line HT-29 is obtained and cells are grown in modified McCoy’s 5A medium supplemented with 10% fetal bovine serum. To study the effect of pyrrolidinedithiocarbamate ammonium on IL-8 production, HT-29 cells in 96-well plates are induced with 20 ng/mL of IL-1β for 18 h. Various concentrations (3-1000 μM) of pyrrolidinedithiocarbamate or its vehicle (culture medium) are added to the cells 30 min prior to IL-1β stimulation. The concentration of IL-8 in the supernatant is determined using solid-phase enzyme-linked immunosorbent assay[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration

    Animal Administration: [2]Pyrrolidinedithiocarbamate is administered intraperitoneally to mice at dose levels of 100 and 50 mg/kg. Mice are divided into a DSS-untreated group (normal group), DSS-treated control group, DSS+pyrrolidinedithiocarbamate-treated groupI (low-dose group), and DSS+pyrrolidinedithiocarbamate-treated groupII (high-dose group). In each group, the disease activity index score (DAI score), intestinal length, histological score, and the levels of activated NF-κB and inflammatory cytokines (IL-1β and TNF-α) in tissue are measured[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 6.0868 mL 30.4340 mL 60.8680 mL 152.1699 mL
    5 mM 1.2174 mL 6.0868 mL 12.1736 mL 30.4340 mL
    10 mM 0.6087 mL 3.0434 mL 6.0868 mL 15.2170 mL
    15 mM 0.4058 mL 2.0289 mL 4.0579 mL 10.1447 mL
    20 mM 0.3043 mL 1.5217 mL 3.0434 mL 7.6085 mL
    25 mM 0.2435 mL 1.2174 mL 2.4347 mL 6.0868 mL
    30 mM 0.2029 mL 1.0145 mL 2.0289 mL 5.0723 mL
    40 mM 0.1522 mL 0.7608 mL 1.5217 mL 3.8042 mL
    50 mM 0.1217 mL 0.6087 mL 1.2174 mL 3.0434 mL
    60 mM 0.1014 mL 0.5072 mL 1.0145 mL 2.5362 mL
    80 mM 0.0761 mL 0.3804 mL 0.7608 mL 1.9021 mL
    100 mM 0.0609 mL 0.3043 mL 0.6087 mL 1.5217 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Pyrrolidinedithiocarbamate ammonium Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Pyrrolidinedithiocarbamate ammonium
    Cat. No.:
    HY-18738
    Quantity:
    MCE Japan Authorized Agent: